Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine novel use of procyanidine oligomer and multimer

A technology with low proanthocyanidins and proanthocyanidins, applied in the field of medicine, can solve the problems of difficult complete excision, strong invasion and metastasis ability, etc.

Inactive Publication Date: 2009-06-17
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition to the characteristics of concentrated necrotic lesions, good use of the microenvironment to support its own survival, and rapid growth, it also has the characteristics of rich blood vessels and strong invasion and metastasis capabilities. It is difficult to completely remove it with traditional surgical treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine novel use of procyanidine oligomer and multimer
  • Medicine novel use of procyanidine oligomer and multimer
  • Medicine novel use of procyanidine oligomer and multimer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1, using human glioma U-87 and U251 cell lines, human leukemia HL-60 cell lines, human liver cancer Hep3B cell lines, human colon cancer Colon-205 cell lines, human Prostate cancer Du-145 cell line and human A549 lung cancer cell line were used as target cells to carry out the inhibitory effect experiment of F2 and F3 on these cells

[0023] 1.1 Materials

[0024] Human malignant glioma cells U-87 and U251, human leukemia HL-60 cell line, human liver cancer Hep3B cell line, human colon cancer Colon-205 cell line, human prostate cancer Du-145 cell line Strains and human-derived A549 lung cancer cell lines: provided by ATCC. DMEM dry powder: available from Invitrogen / Gibco. Fetal bovine serum: purchased from TBD Company. Pancreatin: purchased from Beijing Huamei Biotechnology Co., Ltd. Tetramethylazothiazolium blue (MTT): purchased from Beijing Huamei Shengke Biotechnology Co., Ltd. F2 and F3 were provided by Professor Sun Baoshan of the Portuguese National R...

Embodiment 2

[0033] Example 2. Using the human glioma U-87 cell line as the target cell, the effect experiment of F2 and F3 on the chemotaxis of U-87 cells induced by formyl peptide

[0034] 2.1 Materials

[0035] 48-well chemotaxis plate: purchased from Neuro Probe Company. Polycarbonate membrane: purchased from Neuro Probe Company. Type I rat tail collagen: purchased from Gene Company. Formyl peptide (fMLF): purchased from Sigma. F2 and F3 were provided by Professor Sun Baoshan of the Portuguese National Resource Laboratory.

[0036] 2.2 Method

[0037] The detection of cell chemotaxis adopts the chemotaxis chamber method. The upper hole of the chemotaxis chamber is the U-87 cell suspension pre-incubated with non-cytotoxic doses of F2 and F3 for 1 h, and the lower hole is 10nM formyl peptide. A negative control group (the lower hole is blank buffer solution, the upper hole is blank cell suspension) and a positive control group (the lower hole is 10 nM formyl peptide, and the upper h...

Embodiment 3

[0039] The result is as figure 1 As shown, F2 (2.5 μg / mL, 5 μg / mL and 10 μg / mL) pre-treated U87 cells for 1 h can significantly inhibit fMLF-induced chemotaxis of U-87 cells in a dose-dependent manner. Because F2 (2.5 μg / mL, 5 μg / mL) pre-treated U-87 cells for 1 h did not affect the random migration of U87, the inhibitory effect of F2 (2.5 μg / mL, 5 μg / mL) on fMLP-induced chemotaxis of U87 cells Does not work by affecting its random migration. Similarly, F3 (2.5 μg / mL, 5 μg / mL and 10 μg / mL) pre-treated U-87 cells for 1 h could significantly inhibit fMLF-induced chemotaxis of U-87 cells in a dose-dependent manner. Because F3 (2.5 μg / mL, 5 μg / mL) pre-treated U-87 cells for 1 h did not affect the random migration of U-87, so the F3 (2.5 μg / mL, 5 μg / mL) on the fMLF-induced U-87 cell Inhibition of Chlamylation does not work by affecting its random migration. Embodiment 3, the comparative experiment of the anti-glioma activity of total proanthocyanidins and F2, F3

[0040] 3.1 Ma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
degree of polymerizationaaaaaaaaaa
degree of polymerizationaaaaaaaaaa
Login to View More

Abstract

The invention provides novel application of proanthocyanidin oligomer F2 and a polymer F3 in preparing anti-tumor health care food and medicine, in particular novel application in preparing health care food and medicine for treating glioma. The application researches inhibiting function of F2 on brain tumor, blood system tumor, alimentary canal tumor, respiratory system tumor and urinary genital system tumor. Firstly, F2 and F3 are discovered to have the inhibiting functions on glioma cell strains U-87 and U251, humanized leukemia HL-60 cell strains, humanized liver cancer Hep3B cell strains, humanized colon cancer Colon-205 cell strains, humanized prostate cancer Du-145 cell strains and humanized A549 lung cancer cell strains, and the inhibiting function is improved along with progressive increase of dosage. In addition, the F2 can also remarkably inhibit chemotaxis of human malignant glioma U-87 cells induced by formyl peptide and expression of formyl peptide receptor (FPR) in the cells. The receptor has important function on mediating migration, survival, growth and vasculogenesis of the human malignant glioma cells.

Description

Technical field: [0001] The invention belongs to the technical field of medicine, and relates to new medical applications of proanthocyanidin oligomers (F2) and high polymers (F3), in particular to the preparation and prevention of intracerebral tumors, blood system tumors, digestive tract tumors, and respiratory system tumors. Tumors and genitourinary system tumors, especially the use of health food and medicine for the prevention and treatment of human malignant glioma. Background technique: [0002] Proanthocyanidins (procyanidins or procyanidins, referred to as PC) is a general term for a large class of polyphenolic compounds widely present in plants. Proanthocyanidins from many different plants have been extensively studied over the years. As a natural and efficient antioxidant, it also has many other excellent biopharmacological activities. It has been increasingly favored by people in the fields of nutrition and health care, medicine and hygiene, and cosmetics. It ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D311/62A61K31/352A61P35/00
Inventor 吴春福杨静玉张凤娇孙宝山王立辉赵余庆
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com